Katie Julien, MD
Family Medicine · South Jordan, UTNPI 1386691251
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,105 of the $2,610 with a category attached, or 80.6%. 32 manufacturers reported payments, led by Pfizer at 31.1% of the total.
Across 123 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$811
- AbbVie$547
- Astellas Pharma US Inc$185
- AstraZeneca$124
- Lilly USA, LLC$93
- Amgen$73
- plus $777 from 26 others
Across 1,512 payments — averaging $4705.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.4M
- Modernatx, Inc.$2M
- Merck$1.1M
- Seqirus USA Inc$201K
- Sanofi Pasteur Inc.$170K
- AbbVie$110K
- plus $55K from 4 others
What the payments were for
- Travel & lodging$25810%
- Food & beverage$2,10581%
- Education$2479%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $811 |
| AbbVie(2 entities) | 32 | $547 |
| Astellas Pharma US Inc | 2 | $185 |
| AstraZeneca | 9 | $124 |
| Lilly USA, LLC | 6 | $93 |
| Amgen | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Merck | 9 | $59 |
| Novo Nordisk | 4 | $56 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Abbott | 2 | $42 |
| Organon | 3 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Boston Scientific | 2 | $36 |
| Neuronetics, Inc. | 1 | $35 |
| Inspire Medical Systems, Inc. | 2 | $32 |
| Bayer | 2 | $31 |
| GSK | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,610 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 129 | $184,255 |
| OzempicSemaglutide | 107 | $125,935 |
| TrulicityDulaglutide | 42 | $62,162 |
| MyrbetriqMirabegron | 55 | $51,036 |
| FarxigaDapagliflozin Propanediol | 28 | $31,905 |
| JardianceEmpagliflozin | 16 | $21,210 |
| EliquisApixaban | 14 | $19,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,669 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $9,076 |
| Xtampza ErOxycodone Myristate | 12 | $8,779 |
| CreonLipase/Protease/Amylase | 11 | $8,282 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,930 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,903 |
| Rosuvastatin Calcium | 242 | $3,740 |
| Omeprazole | 179 | $3,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $93 | $246,417171 claims |
| Novo NordiskOzempic | $56 | $125,935107 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $51,03655 claims |
| AstraZenecaFarxiga, Symbicort | $124 | $40,98144 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $31 | $21,59924 claims |
| PfizerEliquis | $811 | $19,03914 claims |
| AbbVieCreon, Synthroid | $547 | $10,27737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in South Jordan
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.